Reintroduction of Heated Tobacco Products in the US Sparks Concerns Over Limited Safety Evidence
Heated tobacco products, often promoted as less harmful alternatives to traditional cigarettes, are making a resurgence in the US market amid limited and inconclusive evidence about their safety. These electronic devices heat tobacco to create inhalable nicotine aerosols, with popular brands like IQOS, Ploom, and Glo. Unlike e-cigarettes, which vaporize a nicotine-laden liquid, heated tobacco products use actual tobacco leaves, yet they are marketed similarly.
Research indicates a lack of comprehensive long-term data on health risks associated with heated tobacco use. A recent review of 40 clinical trials examining molecular biomarkers in blood, breath, and urine found changes linked to heart disease and cancer. However, the evidence was often contradictory and hampered by biases, such as industry funding and controlled study settings that don’t reflect real-world usage.
Most studies suggest that switching from traditional smoking to heated tobacco products might lower some health risks; yet, others show no benefit or potential increased risks. Notably, the majority of the research was industry-funded and short-term, which limits the reliability of these findings.
Heated tobacco products are already prevalent in Japan and have been reintroduced in the US, notably IQOS relaunching in Texas in March 2025 after a temporary removal due to patent disputes. Philip Morris International, a major tobacco corporation, owns many of these products, claiming they offer a "better alternative" for adult smokers. Nonetheless, independent research indicates these claims are unsubstantiated, and the products may not aid cessation efforts, with some data hinting at ongoing health risks.
The long-term impacts remain uncertain, and current evidence does not convincingly demonstrate that heated tobacco products are safer than cigarettes. More independent, long-term studies are needed to assess whether they can truly reduce disease risk and help smokers quit. Until then, health authorities and consumers should be cautious about these products as their safety profile is still unclear.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Lung Cancer Trial Model Promises Faster and More Inclusive Research
The Pragmatica-Lung trial demonstrates a fast, inclusive, and efficient model for lung cancer research, providing valuable insights despite not meeting its primary survival endpoint. This approach could revolutionize future clinical trials in oncology.
Proteoglycan Family Molecules Offer Promising Advances in Breast Cancer Diagnosis and Treatment
Recent research uncovers the potential of proteoglycan molecules as biomarkers and therapeutic targets in breast cancer, promising advances in diagnosis and personalized treatment strategies.
Speedballing: Addressing the Dangerous Union of Stimulants and Opioids in Modern Public Health
Speedballing, the hazardous combination of stimulants and opioids, has become a leading cause of overdose deaths in the U.S. Public health initiatives focused on awareness, treatment, and harm reduction are critical to tackling this evolving crisis.
Allopurinol Recognized as the First Orphan Drug for Marfan Syndrome Treatment
The EMA has designated allopurinol as the first orphan drug for treating Marfan syndrome, opening new avenues for managing this rare connective tissue disorder with vascular complications. Ongoing research explores its potential to prevent life-threatening aortic aneurysms.